Legionellosis after hematopoietic stem cell transplantation.

Fiche publication


Date publication

mai 2021

Journal

Bone marrow transplantation

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis


Tous les auteurs :
Mikulska M, Tridello G, Hoek J, Gil L, Yañez L, Labussière-Wallet H, Passweg J, Xhaard A, Pioltelli P, Caillot D, Michel G, Veelken H, Blaise D, Bruno B, Garcia CB, Itälä-Remes M, Crawley C, Bourhis JH, Kaare A, Arcese W, Parody R, Styczynski J

Résumé

Limited data are available on legionellosis after hematopoietic stem cell transplant (HSCT). The aim of this study was to report the cases of legionellosis and to identify predictors of legionellosis, legionellosis-associated death, and non-relapse mortality (NRM). All cases of post-HSCT legionellosis from the EBMT registry were included and matched with controls in a 3:1 ratio for the analyses of risk factors. In the years 1995-2016, 80 cases from 52 centers in 14 countries were identified (mainly from France, Italy, and Spain). Median time from HSCT to legionellosis was 203 days (range, 0-4099); 19 (23.8%) patients developed early legionellosis (within-day +30 post-HSCT). Patients were mainly male (70%), after allogeneic HSCT (70%), with acute leukemia (27.5%), lymphoma (23.8%), or multiple myeloma (21.3%), and the median age of 46.6 (range, 7.2-68.2). Predictors of legionellosis were allogeneic HSCT (OR = 2.27, 95%CI:1.08-4.80, p = 0.03) and recent other infection (OR = 2.96, 95%CI:1.34-6.52, p = 0.007). Twenty-seven (33.8%) patients died due to legionellosis (44% after early legionellosis), NRM was 50%. Predictors of NRM were female sex (HR = 2.19, 95%CI:1.13-4.23, p = 0.02), early legionellosis (HR = 2.24, 95%CI:1.13-4.46, p = 0.02), and south-eastern geographical region (HR = 2.16, 95%CI:1.05-4.44, p = 0.036). In conclusion, legionellosis is a rare complication after HSCT, mainly allogeneic, occurring frequently within 30 days after HSCT and associated with high mortality.

Référence

Bone Marrow Transplant. 2021 May 22;: